ALZpath and Siemens Healthineers Sign Licensing Agreement  Read the full announcement →

ALZpath Logo
Contact Us

ALZpath Commits to Eliminating the ‘D-Word’ to Reduce Stigma and Support Early Alzheimer’s Detection

Company Joins Global Initiative to Replace Outdated Language with Empowering, Patient-Centered Communication Carlsbad, California, February 2nd, 2025 – ALZpath, Inc., a leader in blood test-based diagnostic solutions for Alzheimer’s disease, today announced it has signed a formal commitment with the Initiative to Change the “D-Word” to remove the word “dementia” from its communications and materials. This […]

ALZpath and Siemens Healthineers Sign Licensing Agreement to Advance Global Access to Blood-Based Alzheimer’s Disease Diagnostic Testing

Siemens Healthineers will utilize ALZpath’s high-performing, proprietary pTau217 antibody in its growing test menu for its Atellica analyzers to enable IVD testing for Alzheimer’s disease CARLSBAD, Calif., December 15, 2025 – ALZpath, Inc., a leading developer of innovative diagnostic tools for Alzheimer’s disease and related dementias, today announced a licensing agreement with Siemens Healthineers for […]

ALZpath Proprietary pTau217 Antibody Wins BioTech Breakthrough Award for ‘Diagnostics Innovation of the Year’

Transformative Antibody Recognized for Advancing Global Alzheimer’s Disease Detection  CARLSBAD, Calif., Nov. 6, 2025 — ALZpath, Inc., a leading developer of innovative diagnostic tools for Alzheimer’s disease, today announced it has been named the winner of the “Diagnostics Innovation of the Year” award by BioTech Breakthrough, a leading independent market intelligence organization that honors excellence in the […]

Global Momentum and Validation Grows at AAIC for ALZpath Proprietary pTau217 Antibody Use in Alzheimer’s Disease Research, Diagnosis, and Treatment

ALZpath pTau217 antibody data included in 37 submissions at AAIC, building on 90 Publications Across 18 Countries demonstrating ALZpath’s superior sensitivity and accuracy in blood-based tests for Alzheimer’s disease CARLSBAD, Calif., July 28, 2025 – ALZpath, Inc., a leading developer of innovative diagnostic tools for Alzheimer’s disease, announced today that data highlighting the ALZpath pTau217 antibody […]

ALZpath Named 2025 BRONZE Edison Award Winner for its Proprietary pTau217 Antibody, a Key Biomarker Driving Blood-Based Alzheimer’s Disease Diagnostics

Edison Awards

The ALZpath Antibody is Integral to Advanced Blood Tests for Early Diagnosis of Alzheimer’s Disease and is Widely Available on Research and Clinical Testing Platforms  CARLSBAD, California, April 7, 2025 — ALZpath, Inc. (ALZpath), a leading developer of diagnostic tools and solutions for Alzheimer’s disease and related dementias, announced it has been honored with the […]

Data Showcasing ALZpath’s Proprietary pTau217 Antibody at AD/PD™ 2025 Demonstrates High Rate of Reliability and Scalability for Alzheimer’s Disease Research and Diagnosis

Findings from Studies on Blood Tests Utilizing the ALZpath pTau217 Antibody – Integral to Many Advanced Assays for Research and Clinical Use – Featured in Seven Oral Presentations and Two Posters CARLSBAD, California, April 1, 2025 — ALZpath, Inc. (ALZpath), a leading developer of diagnostic tools and solutions for Alzheimer’s disease and related dementias, announced […]

ALZpath Adds Biotech Veteran to Board of Directors and Names Prominent Global Researcher as Distinguished Scientific Advisor

ALZpath

Samantha Budd Haeberlein, PhD, Joins the Board; Henrik Zetterberg, MD, PhD, Extends Advisory Role, Adding to a Preeminent Group of Multi-Disciplinary Experts Guiding ALZpath’s Innovation Initiatives CARLSBAD, California, March 25, 2025 — ALZpath, Inc., a leading developer of diagnostic tools and solutions for Alzheimer’s disease and related dementias, announced the addition of Samantha Budd Haeberlein, PhD, […]

ALZpath Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2025

CARLSBAD, California, March 18, 2025 — ALZpath, Inc.,a leading developer of diagnostic tools and solutions for Alzheimer’s disease and related dementias, announced that it has been named to Fast Company‘s prestigious list of the World’s Most Innovative Companies of 2025. Alzheimer’s disease and related dementias are expected to impact nearly 153 million people globally by […]

ALZpath Appoints Mike Banville as CEO

CARLSBAD, California, January 27, 2025 — ALZpath, Inc., a leading developer of diagnostic tools and solutions for Alzheimer’s disease and related dementias, today announced the board’s appointment of Mike Banville as CEO, effective January 1.  Banville replaces Chad Holland, who served in a fractional role as CEO while ALZpath transitioned toward its next stage of development. […]